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Abstract: 
The aim of this paper is to assess the relevance of somatic evolution by natural selection to  
our understanding of cancer development. I do so in two steps. In the first part of the  
paper, I ask to what extent cancer cells meet the formal requirements for evolution by  
natural selection, relying on Godfrey-Smith’s (2009) framework of Darwinian populations.  
I argue that although they meet the minimal requirements for natural selection, cancer  
cells are not paradigmatic Darwinian populations. 
In the second part of the paper, I examine the most important examples of adaptation in  
cancer cells. I argue that they are not significant accumulations of evolutionary changes,  
and that as a consequence natural selection plays a lesser role in their explanation. Their  
explanation, I argue, is best sought in the previously existing wiring of the healthy cells.
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Cancer cells and adaptive explanations
It is very common to read that cancer is “a disease of clonal evolution within the body” (Merlo 
et al. 2006, p. 924). This idea has gained most of its popularity in the last thirty years or so, following  
the publication of well-developed evolutionary accounts of cancer development (most famously Cairns 
1975 and Nowell  1976; for a review of the landmark publications, see Attolini and Michor 2009). 
According to some contemporary authors, “the fundamental problems of neoplastic progression and 
cancer therapy are also problems of evolutionary biology” (Merlo et al. 2006, p. 933). They are not  
simply  saying that  the  study of  the  somatic  evolution  of  cancer  cells  is  a  research  avenue worth 
exploring – a claim that most scientists would certainly second. Their claim is much stronger:
“consensus emerged that somatic (within-body) cellular selection and evolution is the fundamental  
process  by  which  neoplasms  arise,  acquire  malignancy,  and  evade  therapeutic  interventions” 
(Pepper et al. 2009, p. 62, emphasis added)
Despite  this  apparent  consensus,  the  authors  note,  this  view  “has  seldom  been  integrated  into 
biomedical research” (Pepper et al. 2009, p. 63).  Studying cancer as an evolutionary phenomenon, they 
claim, would improve both our understanding of its development and clinical outcomes (Gatenby and 
Gillies 2008; Gerlinger and Swanton 2010; Pepper et al. 2009). Some go further and claim that it is 
necessary in order “to transform cancer research into a rational and predictive science” (Attolini and 
Michor 2009, p. 24).
This opinion has not fallen on deaf ears. Despite thirty years of intense research through Cancer 
Chemotherapy National Service Center, the American medical community concluded in the 1980’s that 
“we are losing the war on cancer” (Bailar and Smith 1986, p. 1226). Since the 1990’s, after even more 
massive investments in cancer research and prevention programs, one can at least claim that clinical 
outcomes are getting better, but progress is painfully slow, and cancer continues to be a major killer  
(Eheman et al. 2012). In this context, the promises of an evolutionary perspective on cancer – which 
purports to explain the very urgent problem of tumour relapse – are attractive. The new approach, if  
heeded,  would  imply  a  major  reorientation  of  research  programmes in  molecular  oncology,  and a 
reshaping of clinical practice (Gatenby and Gillies 2008; Gillies et al. 2012; Heng et al. 2010). It is 
therefore important to evaluate the reasons we have to support these claims. The aim of this paper is to 
assess, from a philosophical point of view, the potential relevance of somatic Darwinian processes for 
the understanding of cancer development1.
To ask whether cancer development should be seen as an evolutionary phenomenon can mean 
two different things: 1) whether (and to what extent) Darwinian processes occur among cancer cells; 
and 2) whether (and to what extent) these processes, if they occur, are useful for the understanding of 
cancer cells and their features. I address both questions respectively in the two main parts of the paper.
In the first part, I ask whether cancer cells meet the formal requirements of evolution by natural 
selection, applying Godfrey-Smith’s (2009) recent account of Darwinian populations. I show that with 
respect  to  this  framework,  cancer  cells  are  much closer  to  normal  somatic  cells  than  is  generally 
suggested, and argue that although they fulfill the minimal requirements for natural selection, they are 
1 By speaking of cancer development, I explicitly wish to avoid discussions of cancer in light of the evolution of 
multicellular life (Frank 2007; Frank et al. 2003; Hutchinson et al. 2003; Buss 1987). What I am interested in is the 
evolution of cancer cells within a given tumour. This also means that I exclude the very special cases of transmittable 
cancers (see for instance Belov 2012).
not paradigmatic Darwinian populations.
This conclusion suggests that cancer cells are unlikely to develop complex adaptations – that is, 
adaptations  that  are  an  accumulation  of  evolutionary  changes.  In  the  second  part  of  the  paper,  I 
therefore examine the best candidate adaptations in cancer cells to determine whether they are the 
result of cumulative evolution. I argue that, for the most part, they are not. Furthermore, I discuss the  
explanatory relevance of natural selection for these cases. While I do not deny the role of natural 
selection, I propose that alternative explanations based on the original molecular architecture of the cell 
do much more explanatory work than invoking natural selection.
Are cancer cells Darwinian populations?
The  best  empirical  evidence  for  natural  selection  within  a  tumour  probably  comes  from 
phylogenetic studies of cancer (sometimes called “tumour archaeology”), which attempt to reconstruct 
a schematic history of the appearance and spread of genetic alterations (see for example Nik-Zainal et 
al. 2012; Anderson et al. 2011; Sabatino et al. 2008). While natural selection is not the only possible 
cause of patterns of genetic heterogeneity (see Nik-Zainal et al.  2012a on DNA damage and repair 
processes),  it  is  quite  uncontroversial  by  now  that  cancer  cells  undergo  differential  persistence. 
Tumours consist of different subclones, and some lineages go extinct while others thrive. The real issue 
is not whether natural selection occurs within a tumour, but what we can expect out of it. In itself, some 
differential persistence is insufficient for paradigmatic evolution (it could be entirely accidental), and 
assessing the relevance of Darwinian processes in cancer development requires an inquiry into the 
conditions of possibility of evolution by natural selection.
Godfrey-Smith’s framework
I claim that the conception of cancer development as an evolutionary phenomenon is  often 
overrated in the scientific literature, and there are two major reasons for this. The first is an unfortunate 
conflation of natural selection and  evolution  by natural selection, with a jump from evidence of the 
former  to  inference  of  the  latter.  The  second  reason  is  a  simplistic  understanding  of  the  formal 
conditions  for  evolution  by  natural  selection,  limited  to  a  rather  weak  reading  of  the  traditional 
requirement of inherited variations in fitness (for instance Ridley 2007). Indeed it is common to read in  
papers about cancer that “[t]he heritable variation of reproductive success in a population is necessary 
and sufficient to cause natural selection” (Merlo et al. 2006, p. 927, emphasis added; see also Pepper et 
al. 2009; Heng et al. 2010). Although these classical criteria are highly relevant to evolution by natural 
selection, many authors (including Godfrey-Smith 2009) have noted that there are counter-arguments to 
both the necessity and the sufficiency of these “ingredients”.  The cells in our body, to start with, meet 
these requirements at least to some degree, but most of them do not undergo paradigmatic evolution by 
natural selection (Godfrey-Smith 2009, p. 56). The conditions of possibility of evolution by natural 
selection  are  more  complex;  first  because  they  depend on more than  the  classical  conditions,  and 
second because each condition can be met to various degrees. Variation, for instance, is required for 
evolution by natural selection, but a population is not said either to have or not to have variation – it  
has a certain amount of variation. Evolution is impossible without a minimum of variation, but too 
much of it will lead to a scenario of “error catastrophe” in which no evolution is possible.
Godfrey-Smith (2009) pays close attention to these complexities. He develops the concept of a 
Darwinian population, which is a population of entities that can be expected to undergo evolution by 
natural selection. He then proposes to view the factors that are relevant to whether a population is 
Darwinian as different dimensions of a space. Figure 1 shows a representation of this space (taking into 
account  only  three  dimensions),  with  sample  kinds  of  populations.  For  our  purposes,  the  most 
important dimensions are the following:
H - Fidelity of heredity
V - Abundance of variation
C - Continuity, or smoothness of the fitness landscape
S - Dependence of reproductive differences on intrinsic character
G - The degree of reproductive specialization
I - Integration, or the extent of mutual dependence
I  will  describe  each dimension in  more detail  when applying them to the case  of  cancer.  For  the 
moment,  what  is  important  to  note  is  that  each  dimension  (for  instance  the  classical  criterion  of 
variation) varies along a continuum, and likewise the extent to which a population is Darwinian varies 
according to its position in this space. Some populations are more Darwinian than others. Although 
there  is  no  clear-cut  threshold,  Godfrey-Smith  identifies  different  subsets  of  populations,  with  all 
shades of grey in-between. Some collections of entities cannot possible undergo natural selection, and 
those  are  not  Darwinian  populations.  Minimal  Darwinian  populations satisfy  the  traditional 
requirements mentioned above, at least minimally. While they can undergo natural selection, some of 
these populations are Darwinian in a “trivial” way, and therefore
“the process described in the minimal concept should not be installed as "the" Darwinian process.  
Significant Darwinian processes have extra features, and these can in some cases be described 
abstractly. So within the area staked out by the minimal concept, we can identify a category of  
paradigm Darwinian populations. This is the kind of system that can produce novel and complex 
organisms, highly adapted to their circumstances.” (Godfrey-Smith 2009, p. 6, emphasis added)
I will return to the issue of complex adaptations in the second part of this paper. For the moment, what 
matters is that assessing the significance of natural selection for the study of cancer requires more than 
asking  whether  natural  selection  obtains  in  tumours,  or  whether  cancer  cells  are  a  Darwinian 
population. The question is rather what kind of Darwinian population cancer cells are, or at least how 
Darwinian they are2. 
Godfrey-Smith’s framework is therefore more precise in its understanding and assessment of 
the conditions of possibility of evolution by natural selection. Furthermore, it is particularly well suited 
to address evolutionary issues between different levels of biological organization. When dealing with 
populations  at  multiple  levels,  for  instance  the  population  of  cells  in  my  body  and  the  human 
population, the extent to which the population at each level is Darwinian depends on how Darwinian 
those at other levels are. According to Godfrey-Smith, multicellular organisms could be entities of a 
Darwinian population only by de-Darwinizing their component cells at least to some extent. Darwinian 
processes at the cellular level impedes Darwinian processes at the level of organisms. Two of Godfrey-
Smith’s dimensions, integration (I) and reproductive specialization (G), are precisely meant to capture 
this inter-dependency and clarify the ways in which “[o]ne Darwinian population can ‘de-Darwinize’ 
others.” (Godfrey-Smith 2009, p. 9). As these dimensions will be of particular relevance to the case of 
cancer, it is worth sketching them here.
The degree of integration (I) is “a summary of such features as the extent of division of labor, 
the mutual dependence (loss of autonomy) of parts, and the maintenance of a boundary between a 
collective and what is outside it” (Godfrey-Smith 2009, p. 93). Our body has a very high level of 
integration, for most cells depend on those of the digestive tract to digest nutrients, or on those of the  
immune  system  to  protect  them  from  pathogens,  etc.  This  interdependency  prevents  effective 
competition between somatic cells, but in doing so it allows the whole organisms to undergo Darwinian 
processes. Likewise, reproductive specialization (G) makes somatic cells depend on germ cells for the 
long-term reproduction of their genes, impairing Darwinian processes at the level of cells and enabling 
it at the level of organisms. As a consequence somatic cells are “evolutionary dead-ends”, and the same 
applies  within  the  lifetime  of  the  organism:  in  general  tissue  architecture  displays  the  same 
reproductive specialization. In most tissues, differentiated cells have a very short lifespan and limited 
replication potential, and regeneration is assured by a small population of stem cells3. Within the time-
frame of the organism’s lifespan, terminally differentiated cells are also evolutionary dead-ends, while 
stem cells can persist throughout our lifetime4. 
In discussing these dimensions, Godfrey-Smith mentions cancer explicitly. According to him, 
multicellular organisms evolved by de-Darwinizing their somatic cells, and cancer is a reversal of this 
process. Cancer is a “consequence of cell-level Darwinian processes” (Godfrey-Smith 2009, p. 101). 
Although Godfrey-Smith clearly considers cancer to be essentially an evolutionary phenomenon, he 
does not address the issue in any detail. Here, I attempt to do so, and closer inspection reveals a more 
complex story.
The assessment of how Darwinian a population is implies measuring the position of cancer cells 
on each dimension. As it would be extremely complex, if at all possible, to do so in a quantitative or 
absolute manner, I suggest to think of their position relative to normal somatic cells. Godfrey-Smith’s 
interpretation  implies  that  the  different  constraints  placed  on  somatic  cells  to  avoid  Darwinian 
processes are somehow lifted in cancer cells. My strategy, therefore, is to inspect those differences, and 
2 Rather than a simple gradient of more or less Darwinian populations, the multi-dimensionality suggests that there are 
different kinds of Darwinian processes. Godfrey-Smith (2009) does not explore this in depth, and neither will I do so 
here.
3 These stem cells divide asymmetrically to produce an identical daughter (so that the stem cell pool persists) and a 
progenitor cell (which proliferates very quickly but only up to a certain point). Grompe (2012) provides a short but 
enlightening review of tissue stem cells and their technical implications.
4 In fact, many authors have suggested that tissue architecture is an adaptation against cancer (Frank and Nowak 2004; 
Frank et al. 2003).
investigate  whether  the changes  occurring in  carcinogenesis  correspond to significant  shifts  in  the 
dimensions of his framework. Therefore, among the different dimensions characterized by Godfrey-
Smith, I concentrate on those that are especially expected to be different in cancer cells. After a brief  
primer on cancer, I will address each of the relevant dimensions.
Cancer cells and models of carcinogenesis
Cancer  is  uncontrolled  cell  growth,  but  the  different  types  of  cancer  are  extremely 
heterogeneous.  Despite  this  heterogeneity,  cancer  is  characterized  by  features  at  the  cellular  level 
(mostly),  termed the  “hallmarks  of  cancer” (Hanahan and Weinberg 2011;  Hanahan and Weinberg 
2000). These features can be summarized in the following way:
• self-sufficiency in growth signals and insensitivity to inhibition signals
• evasion of apoptosis (cancer cells do not die or go into senescence when they should)
• immortality (cancer cells replicate indefinitely, avoiding Hayflick’s limit)
• angiogenesis (cancer cells induce the creation of blood vessels providing nutrients and oxygen)
• invasion (cancer cells can grow independently from tissue anchoring)
According to the accepted model of carcinogenesis – the multiple-hit theory (Armitage and Doll 1957; 
Vogelstein and Kinzler 1993) – cells  must acquire a series of (semi-)specific mutations to become 
cancerous. The hallmarks of cancer, therefore, were presented as an abstract representation of the kinds 
of mutations required for cancer (Hanahan and Weinberg 2000). The reasoning rests on the assumption 
that those features are not present in normal somatic cells. While this is true of most cells, normal stem 
cells have a lot in common with cancer cells, and this similarity is the ground for an alternative model  
of cancer development: the Cancer Stem Cell (CSC) model.
The CSC hypothesis is a model of cancer development originally developed for leukaemia (for 
reviews  of  the  model,  see  Frank  et  al.  2010;  Visvader  and  Lindeman  2012).  The  model  initially 
proposed that cancer cells are abnormally stopped in their differentiation process. Nowadays, it is taken 
to  mean that a  very small  subpopulation of tumour cells  (the CSCs),  endowed with stem cell-like 
properties,  accounts  for  the  maintenance  and  progression  of  the  tumour.  The  model  is  therefore 
independent of whether CSCs have these stem cell-like properties because of serial mutations which 
reverted their  differentiation,  or also because the oncogenic transformation occurred in a stem cell 
which already had some of these features. However, the latter hypothesis – called the cell-of-origin 
hypothesis – is often joined to the CSC hypothesis (see Barker et al. 2009 for evidence of the stem-cell  
origin of intestinal cancer). In any case, only CSCs have the potential for indefinite self-renewal, but 
they are relatively quiescent (they do not replicate often), dividing mostly asymmetrically, like normal 
stem cells,  to  give rise to  short-lived but  more proliferative cells.  Without  the CSCs,  proliferation 
would quickly stop, and this idea has nourished the hope of finding a “magic bullet” – a targeted drug.
Today it is widely accepted that at least myeloid leukaemia follows a CSC model, and CSCs 
have also been reported in breast cancer (Pece et al. 2010; Dick 2003), brain tumours (Singh et al.  
2003), and many other types of cancer (Frank et al. 2010). Even in these tissues, however, the issue is 
still debated. The great hype surrounding the model, which is evident in the scientific literature, has 
promoted  the  idea  that  all  cancers  follow a  CSC model.  In  fact,  however,  it  is  still  far  from an 
established fact in most solid cancers (see Maenhaut et al. 2010). Cancers like melanoma, that display 
huge genetic instabilities and develop from tissues without a very entrenched developmental hierarchy, 
are very unlikely to follow a CSC model  in any meaningful way.  The last  emphasis is  important, 
because just like the question of whether cancer is an evolutionary phenomenon, whether a cancer 
follows a CSC model is a matter of degrees. This is a direct consequence of the vagueness of the CSC 
model, which specifies neither how rare nor how stable the cancer stem cells should be. Both models of 
carcinogenesis  are  just  that  –  models  or  approximations.  As  a  commentator  noted,  “the  collective 
evidence suggests that various tumours may span the spectrum between the extremes represented by 
the two models” (Adams and Strasser 2008, p. 4018). This is often overlooked by the literature, but it is 
a very important point both for the meaning of the CSC model and, as I will show in a moment, for the  
prospect of evolution.
The upshot of this short overview is that different types of cancers will most likely occupy 
slightly different positions in Godfrey-Smith’s framework. It would be impracticable to address each 
cancer type here, but when there will be significant differences I will consider the two extreme cases:  
cancers that are paradigmatic of the CSC model (like myeloid leukaemia) versus those that are not 
(like, most probably, melanoma).
With this background laid out, I will now attempt to locate cancer cells in Godfrey-Smith’s 
spatial framework by addressing, in turn, the most relevant to the case of cancer.
Abundance of variation (V) and fidelity of heredity (H)
With some exceptions5, mammalian somatic cells are very stable genetically. Cancer cells share 
the  mechanisms  of  heredity  of  their  normal  counterparts,  but  they  are  known  for  their  genetic 
instability: mutations are much more frequent, and sometimes reach surprising levels (see Stephens et 
al. 2011 for a dramatic example; for a review, see Stratton 2011). Cancer cells often exhibit thousands 
of genetic modifications, including major genetic aberrations such as chromosomal loss, gain or fusion. 
Variation (V) is considerably more abundant than in normal somatic cells, and certainly sufficient for 
evolutionary  change.  In  fact  the  extent  of  variation  might  suggest  that  fidelity  of  heredity  (H)  is 
dangerously  low,  but  there  is  compelling  evidence  against  this  view.  In  most  examples,  the  least 
genetically stable cell populations are also the most aggressive (see for instance Anderson et al. 2011; 
Ye et al. 2009; Maley et al. 2006), which strongly argues against an “error catastrophe” scenario.
The correlation between heterogeneity of the tumour population and bad prognosis has long 
been known to the medical community. While it is difficult to say whether the bad prognosis and the 
heterogeneity are both consequences of a common cause, namely the tumour being in a more advanced 
state, there seems to be an independent association (Maley et al. 2006). This is often explained from an 
evolutionary point of view: lower variation would mean fewer possibilities for evolutionary change, 
and consequently for the development of resistance to selection pressures such as therapy6. It must be 
noted, however, that the correlation is not in itself evidence for the activity of natural selection. In fact, 
5 B-cells are systematically cited as the exception to this rule, but it must be noted that the list of “exceptions” is 
beginning to grow at a disturbing pace. See for instance the work of Gage's lab on LINE-1 retrotransposons, most 
importantly in the central nervous system (Singer et al. 2010).
6 Proponents of the CSC model argue that heterogeneity and bad prognosis are both consequences of a common cause: the 
cancer stem cells being blocked early in the differentiation tree. The less differentiated they are, the more their progeny 
can differentiate heterogeneously, and the greater their capacity for self-renewal (hence the severity of the cancer). 
However, the two explanations are not aimed at the same kind of heterogeneity. The evolutionary explanation explains 
the relevance of genetic heterogeneity, while the CSC model is aimed at phenotypic heterogeneity – an heterogeneity 
that is the consequence of varied differentiation rather than mutation.
past selection implies a reduction of heterogeneity7, so that very fit (hence aggressive) populations of 
cancer cells should be less heterogeneous, contrary to the observed correlation. What the correlation 
does suggest, is that therapy  will be a strong selection pressure, and that genetically heterogeneous 
tumours have better chances of getting through it. In any case, different strands of evidence suggest that 
the instability of cancer cells helps rather than hampers their evolution (see also Beckman and Loeb 
2006). Although it is still  unclear whether fidelity of heredity is ideal for evolution, we can safely 
consider it within the required range. The next dimensions, however, are not so easy to settle.
Continuity or smoothness of the fitness landscape (C)
Godfrey-Smith presents this dimension through the metaphor of the fitness landscape:
“We  imagine  properties  of  organisms  (or  sometimes,  populations)  represented  in  several 
dimensions, and fitness represented with another dimension, visualized as height. So mountains (if  
there are any) correspond to areas of high fitness, valleys to areas of low fitness. [...] we have a 
‘‘smooth’’ landscape when similar organismic properties are associated with similar fitness values.” 
(Godfrey-Smith 2009, p. 57)
The  fitness  landscape  is  discontinuous  or  rugged  if  small  changes  in  a  trait  lead  to  dramatic 
consequences on fitness. The magnitude of the effect is not very relevant in itself: what matters is that 
the slope between two points can be more or less accurately predicted from the slope between nearby 
points. The logic is that an evolutionary process with good fidelity of heredity and adequate variation 
will tend to climb up nearby hills of the fitness landscape, provided that it is smooth enough. In other  
words, smooth hills are evolutionary attractors: nearby states are attracted to it, so that they are likely to 
be found, and random departures from it will tend to return to it. In addition, smoothness allows to 
leave local hills and explore other regions of the landscape without immediately falling into a “hole” 
(i.e. without very important losses of fitness). When the landscape is rugged, however, there is little  
margin  for  exploration  and the  number  of  evolutionary  roads  to  a  peak  is  reduced.  According to 
Godfrey-Smith, while high continuity is not strictly required for minimal natural selection, it is needed 
for paradigmatic evolutionary change.8
Given the abstract and metaphorical nature of the fitness landscape, as well as the difficulty of 
clearly  individuating  the  dimensions,  C is  particularly  difficult  to  assess.  Nevertheless,  there  are 
reasons to believe that if it is any different between cancer cells and normal cells, the fitness landscape 
should be more rugged in cancer cells. This is best seen by looking at the robustness of cellular states.  
As Godfrey-Smith  (2009)  explains,  our  cells  have  evolved many mechanisms,  such as  heat-shock 
proteins, which make development more robust to both internal and environmental variations, thereby 
increasing C. The robustness of differentiation into specific cell types (in other words, the smoothness 
of the epigenetic landscape) likewise increases C, for it allows some parameters to vary slightly without 
altering development too much. Systems biology has proposed to see cell types as attractor states, so 
that small variations around a state tend to converge to it. However, Huang (2011) proposes that the 
cancerous state of a cell, as opposed to normal cell types, is a “non-evolved attractor”: akin to spandrels 
(Gould and Lewontin 1979), cancerous states are structural consequences of the epigenetic landscape. 
As they are located in a portion of the epigenetic landscape not normally used, they have been “out of 
7 For a discussion of this issue, see Shibata's (2006) comment on the results presented by Maley et al. (2006)
8 It should be immediately obvious that different traits or regions of the fitness landscape will be continuous to different 
degrees. There will be areas that are more “rugged” than others. Different features of a population might fare differently 
with respect to dimension C, and hence might be expected to evolve at different rates and to different extents. In 
principle, this does not prevent us from assessing C for the whole landscape, although in practice this is beyond reach. 
What it does mean, however, is that this dimension could be of use in a more fine-grained analysis.
reach for fine-tuning by organismal evolution” (Huang 2011, p. 194). In other words, while metazoan 
evolution has in general worked to make the normal regions of the epigenetic landscape smoother, 
thereby  increasing  robustness  and  also  making  the  local  fitness landscape  smoother,  no  such 
“polishing” has occurred for cancer states.  This suggests that if  there is a difference in  C  between 
healthy and cancerous cells, we should expect a lower C in the latter.
Integration (I) and Reproductive Specialization (G)
Cancer cells are generally depicted as “renegade cells”, or “selfish cells”, in comparison to our 
normal somatic cells which live in a highly integrated community. While there is certainly some truth 
in this description (indeed, cancer cells often bring about the death of their host), it must be tempered: 
in reality, cancer cells form “complex tissues” (Hanahan and Weinberg 2000, p. 60), or even “organ-
like populations” (Miller et al. 2005, p. 25; see also Soto and Sonnenschein 2004; Bissell and Radisky 
2001),  showing  a  surprising  degree  of  integration9.  In  Godfrey-Smith’s  framework,  the  classical 
example  of  integration  (I)  is  division  of  labour,  which  arguably  does  not  obtain  in  tumour  cells. 
Nevertheless, it has been demonstrated that in epithelial cancers (the majority of cancers), progression 
often  depends  on  the  interaction  between cancer  cells  and normal  epithelial  cells  (Bhowmick and 
Neilson 2004; Bissell and Radisky 2001). Even cancer cells exhibit some degree of mutual dependency. 
For example, one of the hallmarks of cancer is angiogenesis, the process by which cancer cells induce 
the formation of new blood vessels, thereby ensuring the tumour a flow of nutrients and decreasing its 
concentration of carbon dioxide. In the past ten years, this process has received a lot of attention as a 
potential target for adjuvant therapy (see for instance Corada et al. 2002). For our discussion, what 
matters is that the formation of new blood vessels requires the orchestrated action of many cells, and 
affects the tumour as a whole: blood vessels do not serve single cells, but rather a whole region of the 
tumour. Therefore, it seems unlikely that cells promoting angiogenesis can gain a significant fitness 
advantage over the nearby cells – those with which they directly compete. To put it in Godfrey-Smith’s 
terms, the cells in a tumour might be too integrated to fully compete with one another. Obviously, this 
does not apply to all fitness differences, but it might be extended to some other hallmarks, and it is  
especially relevant for the interactions between the tumour and the immune system. In general, the 
growing recognition that  tumours display a higher level  of integration than was originally thought 
makes our picture of cancer cells as renegade cells clearly over-simplified.
The most important kind of mutual-dependency is  arguably reproductive specialization (G). 
Within the confines of our body, this takes the form of tissue architecture. One might think that this is 
irrelevant to cancer cells, generally pictured as outlaws of tissue architecture, proliferating for their own 
good. However, the Cancer Stem Cells (CSC) model presented earlier suggests that many cancers have, 
in fact, a tissue architecture. And this is most crucial to the somatic evolution of cancer cells.
Even in a cancer which follows the CSC model perfectly, some differentiated cells (non-CSC) 
will  have more reproductive success than others, and therefore we may expect natural selection to 
occur  within  these  populations.  However,  since  they  have  a  very  limited  replication  potential, 
cumulative evolution is very unlikely. Even if it occurred, its product would quickly be lost and would 
certainly be of no clinical relevance. Though in a very short time frame every cancer cell reproduces, 
on a slightly larger scale (i.e. a dozen replications), more relevant to oncology, only CSC can undergo 
long-term reproduction. This corresponds to a high reproductive specialization, but it does not exclude 
significant Darwinian processes among the CSC population. These, however, are by definition very 
few, and as quiescence is among their properties, they seldom reproduce. Moreover, the model predicts 
9 For a philosophical discussion of this issue, see Bertolaso 2011.
that when they do reproduce, it is to give rise to, on the one hand, an identical daughter, and on the 
other a differentiated lineage. This means that the CSC population does not expand, and that the only 
expanding lineage is reproductively limited. In both subpopulations, therefore, cumulative evolution 
seems very unlikely.
However, as I mentioned already the CSC model is an idealization, and fits actual cancers only 
to some degree. It does not specify, for instance, how rare the CSCs must be. If there are only a couple  
of CSCs in their respective niche, evolution seems impossible. But what if 10% of the tumour cells are  
cancer stem cells? And what if, as evidence seems to suggest, they do not only divide asymmetrically, 
but also symmetrically, increasing the CSC pool rather than giving rise to a differentiated lineage? 
Even if the other cells did not evolve, these 10% might. Likewise, what if (as I suggest in the next 
section) cells can switch from and to a CSC-state? The probability of such events will vary a lot across 
contexts, and so will the degree of reproductive specialization. In myeloid leukaemia, G is very high; it 
is already slightly lower in some other forms of leukaemia, and it is certainly very low in melanoma. 
For most cancers, it is reasonable to consider the degree of reproductive specialization sufficiently low 
for minimal Darwinian processes, but not low enough to rank cancer cells as paradigmatic Darwinian 
populations.
Dependence of fitness differences on intrinsic characters (S)
Reproductive specialization and mutual-dependency between cells are special ways of making 
the fate of a cell more dependent on factors external to it, but they are not the only one. Godfrey-Smith 
characterizes this more general kind of dependency in dimension S:
“S is the extent to which ‘realized’ fitness differences in a population are tied to differences in  
intrinsic  character.  [...]  If  extrinsic  features  are  most  of  what  matters  to  realized  fitness  — if 
intrinsic character is not very important — then other than this physical wandering, not much can 
happen.” (Godfrey-Smith 2009, pp. 54-55 )
Of course, virtually every fitness difference depends on the environment, and therefore is not entirely 
intrinsic. As the author emphasizes, however, some differences are almost completely extrinsic:
“When differences in reproductive output depend mainly on things like location – on who is in the  
right place at the right time – and these extrinsic differences are not the result of other intrinsic  
features – we have a low S.” (Godfrey-Smith 2009, p. 54)
There is clearly something relevant in this distinction: when most fitness differences are due to sheer 
spatio-temporal accidents (Godfrey-Smith gives the classical example of the lightning bolt), evolution 
by natural selection is greatly hampered10.
Godfrey-Smith mentions the dependence of fitness differences on intrinsic characters (S) as an 
essential reason why our somatic cells are not paradigmatic Darwinian populations:
“But another factor is the suppression of S. Much of what determines whether a cell divides or not 
is how it is located in relation to other things, which inundate it with signals, control its nutrients,  
and interfere  with it  if  it  behaves abnormally.  Cell  fitness  is  not  very closely tied to  intrinsic  
10 As Godfrey-Smith acknowledges, the notion of intrinsicality is philosophically very problematic. I believe it is not the 
best way to make sense of this dimension. Wholly external fitness differences can lead to evolution by natural selection 
(see for instance Bouchard 2008), and a better way to understand the dimension would be in terms of the stability of the 
fitness differences over lineages. However, as the full elaboration and defence of this account is beyond the scope of this 
paper, I will here keep to Godfrey-Smith's characterization of the dimension. I therefore assume that in most cases, the 
dependence of fitness differences on intrinsic characters is a reliable proxy for the stability of the differences.
character.” (Godfrey-Smith 2009, p. 56)
Our somatic cells are de-Darwinized populations, at least in part because of a very low S. In contrast, 
he continues, cancer cells are re-Darwinized by increasing S. Godfrey-Smith’s story is in line with the 
hallmarks of cancer previously mentioned, among which one can find the self-sufficiency in growth 
signals and insensitivity to inhibition signals. These features make the fitness of individual cancer cells 
(within the organism’s life) less dependent on outside signals and more dependent on intrinsic features.
This  account,  while  not  erroneous,  is  incomplete.  The  importance  of  the  tumour  micro-
environment is currently being emphasized in different fields of cancer biology. For example, it has 
been shown that cancer cells are “normalized” to their context, in other words they are transformed by 
their  environment to conform to the tissue in  which they are present (Rubin 2006).  A particularly 
relevant case where the micro-environment plays a major role in the fate of cells is stem cell niches. In 
most  tissues,  stem cells  are  located  in  a  particular  micro-environment  (e.g.  the  bone  marrow for 
hematopoeitic stem cells) that protects them and maintains them in an undifferentiated state. Recently, 
the role of the niche in the maintenance of stem cells has been emphasized by a number of studies 
showing, among other things, the capacity of the niche to de-differentiate somatic cells back to stem 
cells (Voog and Jones 2010; see also Kai and Spradling 2004). Assuming that the tumorigenic mutation 
occurs  in  a  stem  cell,  the  niche  could  protect  it,  ensure  its  self-renewal  (notably  by  keeping  it 
undifferentiated) and stimulate its proliferation (especially in response to injury). But it also means that 
the niche could transform a differentiated tumour cell into a CSC just because it happened to be there. 
Being a CSC might not be wholly intrinsic to the cell, but might be extrinsic to a large extent. The most  
relevant fitness differences between cells, then, could be due to spatio-temporal accidents.
In fact, the extent to which the fate of cancer cells depends on their environment is so great that 
it seems at odds with the received view on carcinogenesis. As mentioned earlier, the traditional model 
of carcinogenesis states that cancer is caused by the accumulation of semi-specific mutations. Some 
authors,  however,  suggest that these mutations are merely permissive rather than causative (Huang 
2011; see also Heng et al. 2010). While this view is not widespread, some important phenomena seem 
to support it. First, it has been demonstrated that transformation and hyperproliferation can be induced 
(with complete  penetrance)  in  epithelial  cells  through genetic  intervention on adjacent  cells  of the 
micro-environment (Bhowmick et al. 2004; see Bhowmick and Neilson 2004 for a review). Likewise, it 
seems that the tumorigenic phenotype can be reverted much more easily than the received view would 
suggest: some cancer cells, when injected in an embryo, lose their cancerous phenotype (Bussard et al. 
2010; Gardner 1975). The same “reprogramming” can be done with oocyte extracts (Allegrucci et al. 
2011) or by transplantation of the nucleus of cancer cells  into oocytes (Hochedlinger et  al.  2004). 
Furthermore,  it  has  been  reported  that  in  some  cases  the  cancer  cells  injected  in  embryos  were 
compatible  with  the  normal  embryonic  development  (Mintz  and  Illmensee  1975)11.  Such  major 
phenotypic transformation is not limited to drastic laboratory manipulations, but has also been shown 
to occur within a tumour: for instance, changes in the stroma strongly modulate tumour growth (Bissell 
and Radisky 2001; Boudreau et al. 1995). Obviously, since these changes restrain proliferation, they 
decrease the fitness of the cells. If cues from the micro-environment determine much of the fitness of 
cells, then the situation is not so different from normal somatic cells.
Godfrey-Smith is certainly right that cancer cells are less determined by their environment than 
11 Since some years later Karl Illmensee fraudulently reported the cloning of mice (see Kolata 1998), one should be careful 
in interpreting the results of Mintz and Illmensee's (1975). Hochedlinger et al. (2004) were able to obtain viable 
chimeric mice by transplanting the nucleus of melanoma cells into oocytes, but these mice showed a very high cancer 
susceptibility.
normal cells, but to picture them as self-determined would be a mistake.  S  is significantly higher in 
cancer cells than in normal somatic cells, but it is far from being maximal.
Taking stock
Let us now summarize our evaluation of cancer cells. Cancer cells have sufficient variation (V) 
for evolutionary change, and although their relatively low fidelity of heredity (H) might threaten the 
possibility  of  complex adaptation,  it  is  generally  in  the range compatible  with minimal  Darwinian 
processes. However, cancer cells display a level of integration (I) reminiscent of organs, and share 
reproductive fate to an important extent. Much of the fitness differences between cells does not depend 
on their intrinsic features (S), which strongly suggests that these differences cannot be the basis for 
paradigmatic  Darwinian processes.  Perhaps the most  crucial  dimension, the degree of reproductive 
specialization (G) will vary from case to case, depending on the extent to which a given cancer follows 
a CSC model. When it does, long-term proliferation will be restricted to a tiny sub-population of the 
tumour (G), rendering most cancer cells unable to accumulate evolutionary changes. A very schematic 
assessment of the dimensions is represented in Table 1.
Population F V C I G S
Paradigmatic Darwinian population +++ + +++ - - - +++
Healthy somatic cells +++ - ++ ++ ++ - -
Cancer cells: ++ + + + +/- -
- CSC-model
(e.g. myeloid leukaemia) ++ + + + ++ -
- Non-CSC
(e.g. melanoma) + ++ + + - +
Table  1: Schematic  position  of  key  populations  in  Godfrey-Smith’s  spatial  framework.  A “+” 
represents a higher value, and “-” a lower value.
It should be uncontroversial by now that cancer cells are in general at least a minimal Darwinian 
population: they have the features required to undergo natural selection. Indeed, as mentioned earlier, 
tumour archaeology is  best  explained by natural selection.  However,  the observations  made in  the 
previous sections have shown that the typical picture of the cancer cell as a renegade cell, freed from 
the de-Darwinizing features of our somatic cells, is over-simplified. The exact position of cancer cells 
in Godfrey-Smith’s space will vary according to the type of cancer, with the degree to which it follows 
a CSC model being of particular relevance. In general, although cancer cells are more Darwinian than 
healthy somatic cells, the difference between them should not be exaggerated. Especially, the tissue 
organization of cancer cells and the dependence of their fitness differences on their microenvironment 
should not be underestimated. Cancer cells are not paradigmatic Darwinian populations (although some 
forms of cancer are closer to it than others). According to Godfrey-Smith’s framework, therefore, these 
processes are unlikely to lead to complex adaptation. In the second part of this paper, I investigate 
whether this is the case by discussing the best candidates for adaptation in cancer cells, and attempt to 
evaluate the explanatory relevance of natural selection in this context.
How important is natural selection to understand cancer cells?
Cancer  cells  are  at  least  minimal  Darwinian  populations,  but  not  paradigmatic  ones.  This 
suggests that although we should expect Darwinian processes to occur (as they do), we should not 
expect  too  much  out  of  those  processes.  According  to  Godfrey-Smith,  paradigmatic  Darwinian 
populations
“are the ones that have great scientific importance. These are the evolving populations in which  
significant  novelty  can  emerge,  the  ones  that  give  rise  to  complex  and  adapted  structures.”  
(Godfrey-Smith 2009, p. 41)
Complexity is notoriously difficult to define, but it becomes more tractable if we think of adaptation as 
a process rather than as an outcome, and consider complex adaptations are the product of cumulative 
evolution.  As Godfrey-Smith suggests,  minimal  Darwinian populations are  unlikely to give rise to 
complex adaptations because they offer “little possibility for "cumulative" change, for evolutionary 
processes involving the successive addition of slight modifications to an existing structure.” (Godfrey-
Smith 2009, p.45). 
The  idea  that  such  an  accumulation  distinguishes  evolution  by  natural  selection  (i.e 
paradigmatic Darwinian processes) from minimal Darwinian processes is present at least implicitly in 
many strands of philosophy of biology. In optimality models, local hill-climbing is paradigmatic of 
adaptations, and “climbing” implies the accumulation of “steps”. More explicitly, Hull et al. (2001), 
who proposed an account of evolution based on processes rather than on conditions or features of 
populations,  considered  that  without  a  strong iterative  component,  a  process  should  not  be  called 
evolution  by  natural  selection.  Sterelny  (2007;  2006)  makes  a  similar  point  in  his  discussion  of 
evolvability,  stating  that  “[t]he  crucial  point  to  remember  is  that  significant  evolutionary  change 
typically depends on the accumulation of smaller changes” (Sterelny 2007, p.13). To say that natural 
selection explains complex adaptations through the accumulation of small changes has nothing to do 
with gradualism: there is no need for this process to be very slow or even regular, nor for the different 
steps  to  be  similar  in  magnitude.  Simply,  it  has  to  be  cumulative  in  order  to  produce  complex 
adaptations. As I will show in the next section, the notion of accumulation can be used to map the 
relative importance of natural selection in the explanation of the resulting adaptation.
The explanatory role of natural selection: a paradigmatic example
The explanatory role of natural selection extends much beyond the simple spread of beneficial 
variations. As Ridley repeatedly emphasized in his famous textbook on evolution, “natural selection is 
the only explanation for adaptation” (Ridley 2007, p. 256, 259). It would have been more correct, 
however, to say that natural selection is the only explanation for complex adaptations. To illustrate this, 
consider first a toy example, which I will supplement in a moment with a real case. Both giraffes and 
humans with the condition of acromegaly (let us call them “giants”) are unusually tall. But the actual 
difference-makers (Waters 2007) differ. If we compare the giants with humans that have a “normal” 
height,  we will  notice  that  the  only  consistent  difference  is  a  mutation  in  the  NSD1 gene.  If  we 
compared, however, the giraffes with their short ancestors, we would most probably notice that their 
difference in height is due to the accumulation of a broader array of changes. The point is that without  
natural selection, a mutation in the NSD1 gene is very unlikely, but the accumulation of all the changes  
making the difference for the giraffe’s height is incommensurately less likely. Independently of whether 
or not acromegaly is fitter than the normal condition, we could expect it to arise once in a while by 
chance. But without natural selection, we would never expect giraffes to arise from short ancestors by 
chance. This is, I believe, the intuition behind Ridely’s statement: while mundane adaptations could be 
accidental, natural selection is the only explanation for complex adaptations.
Let us now examine the relevance of this point more thoroughly in the context of a real case. 
The threespine stickleback (Gasterosteus aculeatus) is often presented as a paradigmatic example of 
evolution  by  natural  selection.  Initially  a  salt-water  fish  found  throughout  the  world,  it  started 
colonizing different fresh-water areas after the retreat of the glaciers. Different populations adapted to 
their new habitats in strikingly consistent manners, offering a recent example of convergent evolution. 
One such adaptation is  the loss of lateral  plates (or reduction of body armour).  Although it  is not 
entirely clear why (Kingsely and Peichel 2007), it is beneficial to have less plates in the fresh-water 
environment. Salt-water populations are almost completely plated (up to 36 plates each side), while 
fresh-water populations have very few plates, and different crosses produce intermediate amounts of 
plates (Kingsely and Peichel 2007). Using quantitative trait loci (QTL) analysis, a method similar to a 
simple analysis of variance, these variations were mapped to four different genetic loci: a major one 
accounting for up to 75% of the variation in plate number, along with three minor loci (Colosimo et al. 
2004). These different loci are not straightforwardly additive, but all have an independent effect. The 
major locus was later identified to be in the Ectodysplasin gene – Eda (Colosimo et al. 2005).12
The chances for an organism to randomly acquire the variation in Eda are low, but the chances 
to randomly acquire the variations at the four loci, on both alleles, are orders of magnitude lower.  
Natural selection, however, makes it much more likely. Since, as was observed, each locus has at least a 
small effect in reducing the number of plates, it  can be assumed that any of these variations, if  it  
appears in a fresh-water environment, will  tend to spread through the population. If each mutation 
arises in some individual and then spreads to the population, it  becomes much more likely for the  
whole combination to appear in a single individual.  Natural selection,  therefore,  is essential  to the 
explanation as it alone can put the explanandum within a reasonable range of likelihood.
Imagine,  on the other hand, a single-locus scenario in which all  observed variation in plate 
numbers would be accounted for by the variation in  Eda  only. Natural selection occurs and has an 
explanatory role in both scenarios, but its explanatory power is much greater in the first case. The main  
difference between the two scenarios is that in the multi-loci case, the trait is a coherent accumulation 
of changes through multiple iterations of natural selection13. It is for the explanation of these complex 
adaptations that paradigmatic Darwinian processes are essential. For more mundane adaptations, which 
are  not  the  results  of  cumulative  evolution,  alternative  explanations  might  be  more  relevant.  The 
important question, therefore, is whether adaptations in cancer cells are accumulated features or not.
Four candidate adaptations in explanations in cancer
It is often held that “the consistent phenotypical changes that emerge during carcinogenesis 
must  always  represent  successful  adaptations”,  and  that  their  “genotypes  and  phenotypes  can  be 
understood according to their roles as adaptive strategies” (Gatenby and Gillies 2008, p. 56, emphasis 
12 For the sake of simplicity, in what follows I make the reasonable assumption that each locus was, throughout the 
evolution of fresh-water sticklebacks, modified respectively through one mutational event. Should it turn out to be 
different, it would only make the case stronger.
13 By cycle or iteration, I do not mean a single generation or reproductive event: rather, it can encompass rounds of natural 
selection up to the fixation of a variant.
added). There are indeed serious candidates for adaptations: cancer cells avoid immune surveillance, 
and  tumour  relapses  suggest  that  they  adapt  to  therapy.  Some  would  even  claim  that  the  very 
phenomenon of carcinogenesis requires an adaptive explanation (see Hanahan and Weinberg 2000). In 
this part of the paper, I therefore turn to the most important of these, and assess the importance of 
natural selection in their explanation. In order to do this, I ask in each case whether the adaptation is an 
accumulation of evolutionary change, and explore alternative explanations.
Evasion of senescence and apoptosis
Upon stress,  most  notably genetic  damage,  normal  somatic  cells  undergo either  senescence 
(stop  replicating)  or  apoptosis  (programmed cell  death).  As I  mentioned earlier,  cancer  cells  have 
considerable genetic damage, and yet continue proliferating. Somehow, therefore, they must avoid this 
normal control mechanism, and this is among the most important hallmarks a cell must acquire to be 
cancerous.  Very  often,  this  is  done  by  mutating  the  gene  TP53:  by  far  the  most  famous  tumour 
suppressor, it  is  mutated in over half  of all  tumours.  A cell  that has lost  p53 activity will  enjoy a 
tremendous advantage over its counterparts. Natural selection will occur very straightforwardly: cells 
without p53 activity will proliferate while the others, ceteris paribus, will stall or die. But this is not the 
result of cumulative evolution. The structure of the transduction pathways regulating apoptosis makes it 
sufficient  to  remove  this  specific  node  (p53)  from the  network  to  effectively  disable  the  control 
mechanism.  The  point  is  made  even  stronger  by  the  fact  that  p53  mutations  are  often  dominant 
negatives (Srivastava et al. 1993; De Vries et al. 2002), which means that a mutation in a single copy of 
the gene is sufficient to prevent the functional copy from doing its work (the mutated protein acts as a 
decoy). In other words, it is not even necessary to mutate both alleles, but a single change is sufficient. 
Knowing this, and looking at the wiring diagram of regulation of apoptosis, p53 appears as an obvious 
weak spot14. Among all alterations that would have been beneficial for the cell, this was a particularly 
easy  one  to  get.  Therefore,  not  only  is  there  no  accumulation,  but  there  is  also  an  architectural  
explanation: the original wiring of the cell leads us to expect, to some extent, the loss of this control 
mechanism.
Contrast this with an alternative scenario in which the molecular network would have a high 
degree of redundancy, for instance by having several copies of the gene encoding for p53 (and without 
dominant negative). In such a context, the original wiring of the cell would not lead us to expect the 
loss of the control mechanism. Should it happen, natural selection would have a lot more to explain – 
indeed  it  would  have  a  great  deal  more  to  accomplish.  In  order  to  lose  all  copies  or  functional 
equivalents,  cells  would  have  to  accumulate  a  series  of  changes  through  many  cycles  of  natural 
selection. If most of these changes, taken individually, make the control mechanisms weaker, each of 
them can be expected to spread. Their accumulation would therefore require an adaptive explanation. 
In the actual scenario, however, cancer cells’ evasion of apoptosis and senescence is not a complex 
adaptation: it is not the result of cumulative evolution, and there are alternative, architectural reasons to 
expect it to arise. Of course, p53 mutation is not always the cause of this cancerous feature, and other  
cases might feature a higher degree of accumulation, but p53 is by far the most common culprit.
Immunoediting and immune evasion
It is a common idea that cancer cells escape immune recognition, and since our immune system 
is  adaptive,  this  seems  to  require  that  cancer  cells  continuously  evolve  escape  mechanisms.  This 
14 Of course, it would have been historically unthinkable to discover the importance of p53 mutations in this way, but this 
is altogether another question.
conclusion rests on the assumption that if tumours did not evolve such mechanisms, they would be held 
in check by the immune system. This is not so obvious (Khong 2002); after all, cancer cells are  our 
cells, not foreign pathogens, and recognizing them from healthy cells is no easy task. As a matter of 
fact, the immune system very often helps tumour progression, for instance by clearing dying cells (see 
Gregory and Pound 2011).  Nevertheless,  there is  strong evidence that  cancer  cells  escape immune 
recognition, and the most famous way through which this is done is the loss of the Human Leukocyte 
Antigen (HLA) system. These proteins are at the surface of cells and present antigens to patrolling T-
cells. Without them, the cells do not present anything and therefore avoid recognition by an important 
portion of the immune system. Assuming that the immune system could normally recognize the cancer 
in this way, the loss of the HLA would be highly adaptive, and one would have to concede that through 
natural selection (immune selection), such an “adaptation” would spread through the tumour. But could 
we really expect the immune system to overcome or sidestep this problem? Will  we really see an 
immune answer, leading into a cyclic arms-race? Apparently, the short is no:
“If cycles of immune pressure and tumor escape were operative during tumor development, one 
might  expect  to  observe  (either  by  examination  or  by  imaging  modalities)  progressive  tumor 
growth that was interspersed with one or more periods of contraction.  Ongoing immunological 
‘shaping’ or ‘sculpting’ of tumors might be expected to result in the destruction of sensitive cells  
followed by proliferation of immunoresistant cells that would, in turn, form the bulk of a new 
tumor emerging from the bed of  the  old tumor.  However,  solid  tumors  generally  do not  have 
growth curves with evidence of significant drops or depressions: tumors simply grow, and then 
grow larger.
[...] Although immune cells can be observed in or around tumors, spontaneous local inflammation 
in an uninfected tumor is generally not seen clinically or histologically.” (Khong 2002, p. 3)
Although we do observe selected changes, such as the loss of the HLA molecules, they are rather one-
shot  changes:  there  is  little  evidence  of  an  iterative  process  of  natural  selection,  much  less  of 
meaningful accumulation of evolutionary change.
Resistance to therapy
The best candidate adaptation in cancer cells is certainly resistance to therapy, analogous to 
bacterial development of resistance against antibacterial agents (Goldie and Coldman 1984). There are 
three major ways in which cancer cells acquire resistance to drugs; each of them, I argue, requires little  
or no accumulation of evolutionary change.
The first is quiescence: since most chemotherapeutic agents (e.g. anthracyclines or mustard gas) 
destroy replicating cells, a simple strategy is to avoid replicating too often. The second way is more 
complex, and consists in preventing drug uptake – in other words preventing the drug to get in the cell, 
or evacuating it. This is most notably done through the activation of the ATP-Binding Cassette (ABC) 
transporters. It is important to note that these first two strategies are both features of at least some of 
our  (non-cancerous)  cells  under  normal  physiological  conditions.  Normal  stem cells,  for  instance, 
prevent  DNA damage  in  part  by  remaining  relatively  quiescent,  and  chemical  cleansing  (mainly 
through the ABC efflux pumps) is a characteristic feature of mesenchymal cells (Singh and Settleman 
2010).  In  fact,  as  Huang notes,  “[t]he rapid development  of  drug resistance can [...]  be seen as  a 
manifestation  of  an  embryonic  program  since  immature  cells  express  an  efficient  detoxification 
program.” (Huang 2011, p.  194).  The same explanation is  given within the CSC model  described 
earlier, according to which some cancer cells, akin to normal stem cells, are quiescent and protected by 
their niche. The CSC model (as well as Huang’s own model of cancer attractor) fully accounts for this 
kind of resistance and for the associated tumour relapse. Because the mechanism was already there, 
waiting to be activated, its appearance in cancer cells is much less surprising.
A third  way  to  resist  drugs  applies  mostly  to  targeted  therapies,  and  implies  reducing  the 
expression of a target or intermediate. Hormone therapy, for instance Tamoxifen, targets an estrogen 
receptor; likewise, immunotherapy targets antigens, and all other targeted drugs either target a specific 
element in a pathway, typically to disrupt it, or are toxic only in the presence of a specific element. In  
all cases we have the same response: if there is any way for the cell to be alive without expressing the  
target, it can simply lose it to acquire resistance. To give only one of the many available examples, it 
was recently shown that melanoma resistance to vemurafenib is due to a loss of exons necessary for the 
drug’s effect (Poulikakos et al. 2011). A cell that has lost the target of a drug with which the patient 
undergoes  therapy,  provided  that  it  is  still  viable,  will  be  selected  for  and  increase  in  relative 
concentration. Again, this is clearly natural selection, but it is not a complex adaptation: they are rather 
one-shot changes that require no accumulation. In fact, very sensitive methods have detected that the 
mutations providing the resistance to a therapy are present before the beginning of the treatment (e.g 
Roche-Lestienne et al. 2002 for Imatinib)15.
In all three cases, cancer cells’ resistance to a therapy is not the result of cumulative evolution.  
Instead, the features were somehow always there, already wired in the architecture of the normal cell. 
But what about resistance to multiple therapies? The question prompts a deeper concern: what if we 
adopt another level of granularity with respect to traits?
The problem of granularity: multi-resistance and cancer initiation
Let us assume that I am right in that neither evasion of the adaptive immune system nor the loss  
of DNA-damage checkpoint are the result of cumulative evolution. The conclusion might hold only 
because  we  think  of  immune  recognition  and  senescence/apoptosis  as  two  independent  selection 
pressures.  If  we adopt  a  more general  perspective and consider  both selection barriers  as  one,  for 
instance “cell control”, then these two changes are accumulated in developing a slightly more complex 
adaptation to circumvent “cell control”. There is no way to “cut traits at the joints”, and the distinction 
between  accumulating  different  adaptations  and  accumulating  different  changes  toward  the  same 
adaptation is not ontological.  We must therefore accept that the amount of accumulation will  vary 
according to the level of granularity. Hence I would grant multi-resistance, provided that the resistance 
to each therapy does not stem from a common alteration, is the result of cumulative evolution and 
therefore that natural selection is essential in explaining it. However, two points must be noted with  
regard to this case.
First, one has to be clear about what exactly is being explained: natural selection explains the 
accumulation of different resistances, but it explains very little of the resistance to a given therapy. Nor 
does it suggest whether resistance to a given therapy is likely to develop or not.
Second,  the  kind of  cumulative  evolution  responsible  for  multi-resistance  has  an  important 
difference with paradigmatic cases of cumulative evolution like the stickleback. Multi-resistance is the 
result of exposure to a series of therapies, and presupposes that a resistance mechanism evolves for 
each therapy. But unlike the four loci in the example of the stickleback, these mechanisms are not  
interchangeable: if resistance to the fourth therapy had arisen during treatment with the first therapy, it 
would  not  have  been  selected  for.  This  means  that  although  natural  selection  makes  the  whole 
combination more likely by fixing the first ones in the population, the relative increase in likelihood is 
considerably lower than in the case of the stickleback, where any of the four loci has an autonomous 
effect of the reduction of plates. In other words, natural selection does play an important explanatory 
15  A recent report also suggests that the stroma commonly confers an “innate resistance” – see Straussman et al. (2012).
role, but not as important as it could be – and it leaves a lot to be explained.
Taking yet another level of granularity, one could consider the cancerous phenotype as a whole 
to  be an adaptation.  Indeed,  it  has  been argued that  cancer  initiation  cannot  be explained without 
natural selection. The multiple-hit theory of carcinogenesis states that cells must acquire a series of 
(semi-)specific mutations to becomes cancerous, but many authors have noted that this is difficult to 
reconcile with the known lifespan and mutation rates of most somatic cells (for instance Smalley and 
Herlyn 2009, p. 1245). Given the frequency of cancer, it seems too unlikely to gather the combination 
of mutations in the short lifespan of a single somatic cell. Hence natural selection was proposed to 
account for this:  if  the first  hit  is  already advantageous for the cell,  it  will  be spread through the 
population,  making the combination of hits more likely by changing the background conditions on 
which the next hit will arise16.  A related – and still  very much debated – hypothesis  is that of the 
“mutator phenotype” (Beckman and Loeb 2006; Loeb 1991), according to which one of the first hits 
increases genetic instability and thereby makes subsequent hits more likely. Once more, however, the 
CSC model provides an alternative explanation which is equally convincing: if cancer either arises in a 
stem cell or revert the cell to a pre-wired stem-cell state, the cell has the necessary lifespan. Moreover, 
many of the hallmarks of cancer are physiological features of stem cells17. Nevertheless, not all cancers 
follow a CSC model, and depending on the case at hand it is likely that carcinogenesis as a whole is a 
cumulative evolution. Once more, it is important to be clear about what exactly is being explained: it is 
neither  the  immortality  of  the  cancer  cell,  nor  its  evasion  of  immune surveillance,  nor  any of  its 
hallmarks. It is only that all the beneficial features, whatever they are, have accumulated.
Taking stock
For cancers that do not follow a CSC model, the process of carcinogenesis as a whole is the best 
candidate for cumulative evolution. This is consistent with the observation that these cancers are more 
Darwinian than cancers following a CSC model. Natural selection can potentially explain why cancer 
is likely despite the low likelihood of randomly accumulating the necessary changes, but it does little 
more.
The other candidate adaptations reviewed here are definitely not complex adaptations.  They 
have an important thing in common: they all consist in the loss of something (generally, of a regulatory 
mechanism). As Huang puts it, in the context of cancer mutations “are not constructive but destructive 
in their action” (Huang 2011, p. 193). Indeed, it seems that cancer cells are limited to either activating 
dormant features or losing evolved ones, and do not develop genuinely new traits – which is, according 
to  Gofrey-Smith,  the “mark of a  significant  Darwinian process.”  (Godfrey-Smith 2009, p.  43).  Of 
course,  logically  a  loss  is  equivalent  to  a  gain  of  the  opposite  trait.  The  point  is  more  about  the 
complexity of the adaptations: the losses occurring in cancer cells all seem one-shot changes rather 
than perfectible, accumulated features. This is consistent with the observation, in the first part of the 
paper,  that  cancer  cells  are  not  a  paradigmatic  Darwinian  population.  Moreover,  it  suggests  that 
alternative explanation might be more relevant. Invoking selection removes very little of the surprise at 
seeing cancer cells evacuate drugs so efficiently. By contrast, showing that mesenchymal cells already 
possess the tools for evacuating chemicals removes a great deal of surprise at seeing this behaviour in 
cancer cells. Far from an isolated case, this seems to be the norm in cancer: to give another example, it 
has  recently  been  demonstrated  that  the  invasive  behaviour  characteristic  of  melanoma  cells  is  a 
16 While there are cases in which all changes appeared together in a single event of massive mutation (Stephens et al. 
2011), they are arguably very rare.
17 Likewise, Huang's (2011) model of unused attractor states offers an equally satisfying explanation.
reactivation  of  the  embryonic  migration  programme  in  the  neural  crest  (Bailey  et  al.  2012). 
Carcinogenesis  itself  is  considered  to  be  analog  to  wound  healing  (Bissell  and  Radisky  2001). 
Certainly, the re-activation has to be due to something, and natural selection is necessary to explain the 
spread of the variation, but in relation to other components of the explanation, its importance has been 
greatly over-rated. 
Conclusion
In the first part of this paper, I have argued that cancer cells are not paradigmatic Darwinian 
populations according to Godfrey-Smith’s framework. Some types of cancer – most significantly those 
that do not follow a CSC model – are more Darwinian than others, but in general cancer cells are much 
farther away from paradigmatic Darwinian populations, and much closer to normal somatic cells, than 
is  generally  assumed.  Consistent  with  this  conclusion,  most  adaptations  (and  arguably  the  most 
important adaptations) in cancer cells are not complex adaptations, in other words they are not the 
result of cumulative evolution, but rather like one-step changes. For this reason, natural selection is not 
the essential component in their explanations. Instead, it is the pre-existing wiring of the cell which best 
accounts for these features. This is not to deny that the changes are selected for, but simply to say that 
the most enlightening explanatory material is already inside the cell, akin to architectural constraints. 
The healthy cells – their structure, possible states, pathways, and weak spots – already contain the 
resources to be drawn upon and developed by cancer cells. It dictates their evolution to a large extent.
The exercise undertaken here has shown the fruitfulness of Godfrey-Smith’s framework in two 
ways.  First,  the  framework was successful  in  guiding the search,  organization and analysis  of  the 
empirical data relevant to the somatic evolution of cancer cells. More importantly, the predictions of 
Godfrey-Smith’s  framework  have  been  corroborated.  Since  cancer  cells  are  minimal  Darwinian 
populations  but  not  paradigmatic  Darwinian  populations,  they  were  expected  to  undergo  natural 
selection but not to develop complex adaptations. In the second part of this paper, I argued that this is 
indeed the case: while there is strong evidence for the action of natural selection, there does not seem to 
be anything near complex adaptations, with the possible exception of carcinogenesis taken as a whole 
in cancers that do not follow a CSC model. Interestingly, this last exception is related to types of cancer 
which are, following Godfrey-Smith’s framework, more Darwinian than those following a CSC model. 
As far as this case is concerned, the framework is consistent with the facts.
I started the paper quoting scientists who claim that “the fundamental problems of neoplastic 
progression and cancer therapy are also problems of evolutionary biology” (Merlo et al. 2006, p. 933). 
It has been argued that the mechanisms underlying cancer, because they are the result of Darwinian 
processes, are so diverse that it would be impossible to catalogue them all (Heng et al. 2010, p. 1080), 
and therefore that traditional molecular oncology is doomed to fail. Many authors claim, for instance, 
that the emergence of resistance is predictable on the ground of natural selection (see Gillies et al.  
2012, p. 490). However, as I have tried to show throughout the paper, cancer cells cannot (see the first 
part of the paper) and do not (see the second part) evolve complex adaptations: they are limited to those 
adaptations  that  are  made  immediately  possible  by  their  original  molecular  architecture.  This 
architecture, therefore, and the possibilities it offers, are better predictors of the emergence of resistance 
than the mere presence of minimal Darwinian processes. Evolution by natural selection plays a role in 
neoplastic progression and in the acquisition of resistance, but “the fundamental problem of cancer”, if 
there is such a thing, is more a problem of cells whose inner workings have vulnerabilities. It is the 
problem of cells which have an inherent potential to become cancerous and resistant to some therapies.
Nevertheless, the dynamic heterogeneity of cancer poses serious challenges to its treatment, and 
(independently of evolutionary accounts of cancer) the medical community is increasingly turning to 
prevention (see for instance the last American “report to the Nation”, Eheman et al. 2012). However, 
one should not confuse the public health question of whether it is more effective to invest in prevention 
or treatment, with the biomedical question of how best to understand cancer and treat its victims. In 
answering the biomedical  question,  it  is  important  to  recognize some of the spectacular  results  of 
molecular oncology, and to persevere in what is arguably the best way of studying cancer biology. 
It is telling that a very recent and extremely interesting study on tumour archaeology, even 
though  it  starts  by  noting  that  “[c]ancer  evolves  dynamically  as  clonal  expansions  supersede  one 
another driven by shifting selective pressures” (Nik-Zainal et al. 2012b, p. 994), contains virtually no 
mention  of  natural  selection.  Discussion  of  selection  or  fitness  occurs  exclusively  in  the  very 
theoretical  introduction,  and the notions are  mentioned nowhere else in the paper,  let  alone in  the 
discussion  of  the  data.  As  this  example  suggests,  natural  selection  seems  useful  to  make  sense, 
abstractly, of the big picture, but we should not expect too much from it. Although an evolutionary 
approach should be integrated to our general understanding of cancer (as is currently being done), I 
believe it should not reorient cancer biology in a major way.
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